14: Immunological products and vaccines
Please select a topic:
14.4 Vaccines and antisera
14.5 Immunoglobulins
Red = Hospital use only
Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee
Page 1 of 5
Date: 1.12.2012
14.4 Active immunity

BCG Intradermal vaccine (BCG SSI®)

Adsorbed Diptheria, tetanus and pertussis (acellular, component) and inactivated polio vaccine (InfanrixIPV)

Adsorbed Diptheria (low dose), tetanus and pertussis (acellular, component) and inactivated polio vaccine
(Repevax)

Adsorbed Diptheria (low dose), tetanus and polio (inactivated) vaccine (Revaxis)

Diptheria, tetanus and pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilys tybe b
conjugate vaccine (Pedicael)

Haemophilus influenzae tybe b and meningitis group C vaccine (Menitorix)

Hepatitis A vaccine – Occupational health only

Hepatitis B vaccine (Engerix B, HBvaxPRO, Engerix B Paediatric)

Influenza vaccine

Measles, mumps and rubella vaccine (MMR Vax Pro, Priorix)

Meningococcal group C vaccine (Meningitec, Menjugate)

Pneumococcal vaccine (Prevenar, Pneumovax II, Prevenar 13)

Varicella-zoster vaccine (Varivax)
Diagnostic agents

Tuberculin PPD 10 units/0.1ml injection

Tuberculin PPD 2 units/0.1ml injection
Prescribing Notes
Vaccines for the childhood immunisation schedule should be obtained from local health organisations or from
ImmForm (www.immform.dh.gov.uk)—not to be prescribed on FP10 (HS21 in Northern Ireland; GP10 in Scotland;
WP10 in Wales).
Preterm birth
Babies born preterm should receive all routine immunisations based on their actual date of birth. The risk of apnoea
following vaccination is increased in preterm babies, particularly in those born at or before 28 weeks postmenstrual
age. If babies at risk of apnoea are in hospital at the time of their first immunisation, they should be monitored for
48 hours after immunisation. If a baby develops apnoea, bradycardia, or desaturation after the first immunisation,
the second immunisation should also be given in hospital with similar monitoring. Seroconversion may be
unreliable in babies born earlier than 28 weeks’ gestation or in babies treated with corticosteroids for chronic lung
disease; consideration should be given to testing for antibodies against Haemophilus influenzae (type b),
meningococcal C, and hepatitis B after primary immunisation.
Red = Hospital use only
Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee
Page 2 of 5
Date: 1.12.2012
Immunisation Schedule
Neonates at risk only

BCG Vaccine
See section 14.4, BCG Vaccines

Hepatitis B Vaccine
See section 14.4, Hepatitis B Vaccine
2 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis
(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)
First dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
First dose
3 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis
(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)
Second dose

Meningococcal Group C Conjugate Vaccine
First dose
4 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis
(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)
Third dose

Meningococcal Group C Conjugate Vaccine
Second dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
Second dose
12–13 months

Measles, Mumps and Rubella Vaccine, Live (MMR)
First dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
Single booster dose

Haemophilus Type b Conjugate Vaccine and Meningococcal Group C
Conjugate Vaccine
Single booster dose
Between 3 years and
4 months, and 5 years

Adsorbed Diphtheria [low dose], Tetanus, Pertussis (Acellular, Component)
and Poliomyelitis (Inactivated) Vaccine
or
Adsorbed Diphtheria, Tetanus, Pertussis (Acellular, Component) and
Poliomyelitis (Inactivated) Vaccine
Single booster dose
Red = Hospital use only
Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee
Page 3 of 5
Date: 1.12.2012
Note: Preferably allow interval of at least 3 years after completing primary course

Measles, Mumps and Rubella Vaccine, Live (MMR)
Second dose
12–13 years (females
only)

13–18 years

Human Papilloma Virus Vaccine
3 doses; second dose 1–2 months, and third dose 6 months after first dose(1)
Adsorbed Diphtheria [low dose], Tetanus, and Poliomyelitis (Inactivated)
Vaccine
Single booster dose
During adult life,
women of childbearing age
susceptible to rubella

Measles, Mumps and Rubella Vaccine, Live (MMR)
Women of child-bearing age who have not received 2 doses of a rubellacontaining vaccine or who do not have a positive antibody test for rubella should
be offered rubella immunisation (using the MMR vaccine)—exclude pregnancy
before immunisation, but see also section 14.4, Measles, Mumps and Rubella
Vaccine
During adult life, if not
previously immunised

Adsorbed Diphtheria [low dose], Tetanus, and Poliomyelitis (Inactivated)
Vaccine
3 doses at intervals of 1 month
Booster dose at least 1 year after primary course and again 5–10 years later
The two human papilloma virus vaccines are not interchangeable and one vaccine product should be
used for the entire course.
(1)
Storage and use
Vaccines should be protected from light. Unused vaccine in multidose vials without preservative (most live virus
vaccines) should be discarded within 1 hour of first use; those containing a preservative (including oral poliomyelitis
vaccine) should be discarded within 3 hours or at the end of a session. Particular attention must be paid to
instructions on the use of diluents. Vaccines which are liquid suspensions or are reconstituted before use should be
adequately mixed to ensure uniformity of the material to be injected.
Red = Hospital use only
Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee
Page 4 of 5
Date: 1.12.2012
14.5 Immunoglobulins

Human normal immunoglobulin 5g injection (Vigam)

Human normal immunoglobulin 750mg (16%) (Subgam – temporary alternative to human tetanus
immunoglobulin.

Human tetanus immunoglobulin 250 unit injection

Anti-D immunoglobulin 500 unit injection (BPL)

Anti-D immunoglobulin 300microgram/3ml syringe (Rhophylac)

Varicella Zoster immunoglobulin
Dose
Consult product literature
Prescribing notes

Supplies of Human Norman Immunoglobulin (Vigam) are strictky controlled throughout the UK and use is
limited to specific approved indications. Please contact pharmacy on ext 2316 prior to prescribing & order
using prescription form for immunoglobulin which can be found at
http://www.departments/medicines/prescriptions.html

Varicella Zoster immunoglobulin should be requested from HPA via On-call Microbiologist.
Red = Hospital use only
Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee
Page 5 of 5
Date: 1.12.2012